Clinical Immunology Communications最新文献_第8页

Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals 老年人先前存在的sars - cov -2特异性T细胞反应的改变

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2021.12.001

Naoyuki Taira , Sakura Toguchi , Mio Miyagi , Tomoari Mori , Hiroaki Tomori , Koichi Oshiro , Osamu Tamai , Mitsuo Kina , Masatake Miyagi , Kentaro Tamaki , Mary K Collins , Hiroki Ishikawa

{"title":"Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals","authors":"Naoyuki Taira , Sakura Toguchi , Mio Miyagi , Tomoari Mori , Hiroaki Tomori , Koichi Oshiro , Osamu Tamai , Mitsuo Kina , Masatake Miyagi , Kentaro Tamaki , Mary K Collins , Hiroki Ishikawa","doi":"10.1016/j.clicom.2021.12.001","DOIUrl":"10.1016/j.clicom.2021.12.001","url":null,"abstract":"<div><p>Pre-existing SARS-CoV-2-specific T cells, but not antibodies, have been detected in some unexposed individuals. This may account for some of the diversity in clinical outcomes ranging from asymptomatic infection to severe COVID-19. Although age is a risk factor for COVID-19, how age affects SARS-CoV-2-specific T cell responses remains unknown. We found that pre-existing T cell responses to specific SARS-CoV-2 proteins, Spike (S) and Nucleoprotein (N), were significantly lower in elderly donors (>70 years old) than in young donors. However, substantial pre-existing T cell responses to the viral membrane (M) protein were detected in both young and elderly donors. In contrast, young and elderly donors exhibited comparable T cell responses to S, N, and M proteins after infection with SARS-CoV-2. These data suggest that although SARS-CoV-2 infection can induce T cell responses specific to various viral antigens regardless of age, diversity of target antigen repertoire for long-lived memory T cells specific for SARS-CoV-2 may decline with age; however, memory T cell responses can be maintained by T cells reactive to specific viral proteins such as M. A better understanding of the role of pre-existing SARS-CoV-2-specific T cells that are less susceptible to age-related loss may contribute to development of more effective vaccines for elderly people.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000135/pdfft?md5=4948698e37d1c2b6c668210a53aeecfa&pid=1-s2.0-S2772613421000135-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86726127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Hepatitis E virus sero-prevalence among pregnant women in Khyber Pakhtunkhwa Pakistan 戊型肝炎病毒在巴基斯坦开伯尔-普赫图赫瓦省孕妇的血清患病率

Clinical Immunology Communications Pub Date : 2022-12-01 DOI: 10.1016/j.clicom.2022.04.001

Shahzad Ahmad Khan , Zafran Khan , Zahoor Alam , Haris Sana , Muhammad Ali , Nasib Zaman , Daniya Ualiveya , Muhammad Rizwan , Muhammad Suleman

{"title":"Hepatitis E virus sero-prevalence among pregnant women in Khyber Pakhtunkhwa Pakistan","authors":"Shahzad Ahmad Khan , Zafran Khan , Zahoor Alam , Haris Sana , Muhammad Ali , Nasib Zaman , Daniya Ualiveya , Muhammad Rizwan , Muhammad Suleman","doi":"10.1016/j.clicom.2022.04.001","DOIUrl":"10.1016/j.clicom.2022.04.001","url":null,"abstract":"<div><p>In Pakistan, the Hepatitis E virus (HEV) is prevalent. HEV exposure is deadly during pregnancy, with high infection rates in both the mother and the baby, even in asymptomatic situations. The researcher examined HEV-negative pregnant women with acute hepatitis or increased renal characteristic assessments at 12 medical sites in Khyber Pakhtunkhwa, Pakistan, to identify maternal and fetal disease risks from August to December 2018. Except for one during the entire pregnancy, twenty-five of the 135 females were HEV-free and in the perinatal period. HEV infection was found in 0.19% of newly pregnant women. Also, 11 cases of forcible induction of labor, 7 cases of normal labor, 5 cases of normal labor (full-term), 2 cases of death, and 1 case of intrauterine death were reported before going to the doctor a girl had an abortion. There were eight postpartum deaths: five from infections, four from miscarriages, and two from miscarriages. While 18 mothers who survived voluntarily or intentionally induced abortions and three women who continued to get pregnant but did not deliver died as a result of abortion. The current study found that HEV infection during pregnancy raised the death rate by 14.2%.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000129/pdfft?md5=bd36dfa074a08228f684a1a5580d5461&pid=1-s2.0-S2772613422000129-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85797420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review 目前治疗阵发性夜间血红蛋白尿的有效性和安全性：一项系统综述

Clinical Immunology Communications Pub Date : 2022-11-23 DOI: 10.1016/j.clicom.2022.11.002

Yara Maria da Silva Pires , Aline de Fátima Bonetti , Jessica Telma Ciecilinsky , Astrid Wiens Souza

{"title":"Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review","authors":"Yara Maria da Silva Pires , Aline de Fátima Bonetti , Jessica Telma Ciecilinsky , Astrid Wiens Souza","doi":"10.1016/j.clicom.2022.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2022.11.002","url":null,"abstract":"<div><p>Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disorder of the pluripotent hematopoietic stem cell. Currently, Eculizumab, Ravulizumab, and Pegcetacoplan are the approved drugs to treat PNH. In order to assess the efficacy and safety of different medications available for PNH, we performed a systematic search. The primary efficacy endpoint was the percentage change in lactate dehydrogenase, transfusion avoidance, and stabilized hemoglobin. Key secondary endpoints included the proportion of patients with breakthrough hemolysis, anemia, adverse events, number of deaths, and discontinuation of treatment. From 2526 articles retrieved from electronic databases and manual searches, a total of five studies were included in this review: 1 observational study and 4 randomized clinical trials. For all efficacy and safety endpoints, Ravulizumab and Pegcetacoplan achieved noninferiority compared with the first standardized treatment Eculizumab. The use of complement inhibition therapy can further improve hematological outcomes in PNH patients.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49749438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pfizer-biontech COVID-19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity. 辉瑞-生物技术公司的 COVID-19 RNA 疫苗接种会诱发一名已存在自身免疫的患者出现磷脂酰丝氨酸自身抗体、低温球蛋白血症和数字坏死。

Clinical Immunology Communications Pub Date : 2021-12-01 Epub Date: 2021-09-27 DOI: 10.1016/j.clicom.2021.08.001

Sandy Nasr, Sara Khalil, Bernard J Poiesz, Katalin Banki, Andras Perl

引用次数: 0

The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination “原始抗原原罪”及其与COVID-19疫苗接种的相关性

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.10.001

Ger T. Rijkers , Frans J. van Overveld

引用次数: 15

Prevalence of asymptomatic SARS-CoV-2 infection in an Austrian cohort. 奥地利队列中无症状 SARS-CoV-2 感染的流行率。

Clinical Immunology Communications Pub Date : 2021-12-01 Epub Date: 2021-10-07 DOI: 10.1016/j.clicom.2021.08.002

Elisabeth Mara, Verena Breitsching, Tanja Schuster, Thomas Pekar

引用次数: 0

Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia 抗端粒酶免疫反应预测慢性淋巴细胞白血病的疾病进展

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.11.002

Claire Germain , Julie Garibal , Valérie Doppler , Fanny Baran-Marszak , Florence Cymbalista , Julien Caumartin , Pierre Langlade-Demoyen , Maria Wehbe , Thierry Huet

{"title":"Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia","authors":"Claire Germain , Julie Garibal , Valérie Doppler , Fanny Baran-Marszak , Florence Cymbalista , Julien Caumartin , Pierre Langlade-Demoyen , Maria Wehbe , Thierry Huet","doi":"10.1016/j.clicom.2021.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.11.002","url":null,"abstract":"<div><p>Human telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell responses were evaluated by IFNγ-ELISpot. Complementary flow cytometry analyses were performed, and data were analyzed in regards of the treatment received by CLL patients afterward and disease progression. Anti-hTERT responses were more frequently observed in non-progressive watch and wait patients, and in progressive patients scheduled to receive ibrutinib, as compared to patients scheduled to receive other types of treatment. <em>In vitro</em>, addition of the anti-PD-1 antibody nivolumab increased anti-hTERT responses. Importantly, Kaplan Meier analyses showed significantly longer progression-free survival in patients with anti-hTERT immune responses at diagnosis as compared to non-responder patients. Our results show that anti-hTERT T cell responses represent a new potential biomarker predictive of CLL clinical outcome.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000093/pdfft?md5=c5397f4fcad6d6a45e72f2543ca6e890&pid=1-s2.0-S2772613421000093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats 新型普鲁兰小孢子菌AFO-202和N-163在Sprague Dawley大鼠体内产生β葡聚糖的有益免疫调节作用

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.11.001

Nobunao Ikewaki , Kadalraja Raghavan , Vidyasagar Devaprasad Dedeepiya , Suryaprakash Vaddi , Masaru Iwasaki , Rajappa Senthilkumar , Senthilkumar Preethy , Samuel JK Abraham

{"title":"Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats","authors":"Nobunao Ikewaki , Kadalraja Raghavan , Vidyasagar Devaprasad Dedeepiya , Suryaprakash Vaddi , Masaru Iwasaki , Rajappa Senthilkumar , Senthilkumar Preethy , Samuel JK Abraham","doi":"10.1016/j.clicom.2021.11.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2021.11.001","url":null,"abstract":"<div><p>The beneficial immunomodulation effects of a biological response modifier glucan (BRMG) produced by two strains of Aureobasidium pullulans, AFO-202 and N-163, have already been reported. Herein, we compared their efficacy on immune-inflammatory parameters in Sprague Dawley (SD) rats. This study was performed on four groups of healthy SD rats, n=6 in each group: Group 1, euthanised on Day 0 for baseline values; Group 2, control (drinking water); Group 3, AFO-202 beta glucan, 200 mg/kg/day; and Group 4, N-163 beta glucan, 300 mg/kg/day. The neutrophil to lymphocyte ratio (NLR) decreased and leukocyte-to C-reactive protein ratio (LeCR) increased in Group 3 (AFO-202) at 15 and 29 days whereas the lymphocyte to C-reactive protein ratio (LCR) increased in group 4 (N-163), within the normal physiological range. These promising results warrant further investigations in larger numbers of healthy and diseased models to develop appropriate strategies for balancing immune system dysregulation.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613421000081/pdfft?md5=e73720ffd1bc8cf7e7a48a584c9882ff&pid=1-s2.0-S2772613421000081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiency 1例古德氏综合征患者和13例常见可变免疫缺陷患者的COVID-19

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.08.003

Hannes Lindahl , C I Edvard Smith , Peter Bergman

引用次数: 2

Antibodies to cytomegalovirus are elevated in myasthenia gravis 重症肌无力患者巨细胞病毒抗体升高

Clinical Immunology Communications Pub Date : 2021-12-01 DOI: 10.1016/j.clicom.2021.09.001

Victoria Probst , Nicole H Trier , Gunnar Houen

引用次数: 0